306 related articles for article (PubMed ID: 15201629)
1. Increased anxiety-like behavior and ethanol self-administration in dependent rats: reversal via corticotropin-releasing factor-2 receptor activation.
Valdez GR; Sabino V; Koob GF
Alcohol Clin Exp Res; 2004 Jun; 28(6):865-72. PubMed ID: 15201629
[TBL] [Abstract][Full Text] [Related]
2. Increased ethanol self-administration and anxiety-like behavior during acute ethanol withdrawal and protracted abstinence: regulation by corticotropin-releasing factor.
Valdez GR; Roberts AJ; Chan K; Davis H; Brennan M; Zorrilla EP; Koob GF
Alcohol Clin Exp Res; 2002 Oct; 26(10):1494-501. PubMed ID: 12394282
[TBL] [Abstract][Full Text] [Related]
3. Subtype-selective corticotropin-releasing factor receptor agonists exert contrasting, but not opposite, effects on anxiety-related behavior in rats.
Zhao Y; Valdez GR; Fekete EM; Rivier JE; Vale WW; Rice KC; Weiss F; Zorrilla EP
J Pharmacol Exp Ther; 2007 Dec; 323(3):846-54. PubMed ID: 17855476
[TBL] [Abstract][Full Text] [Related]
4. Corticotropin-releasing factor (CRF) sensitization of ethanol withdrawal-induced anxiety-like behavior is brain site specific and mediated by CRF-1 receptors: relation to stress-induced sensitization.
Huang MM; Overstreet DH; Knapp DJ; Angel R; Wills TA; Navarro M; Rivier J; Vale W; Breese GR
J Pharmacol Exp Ther; 2010 Jan; 332(1):298-307. PubMed ID: 19843974
[TBL] [Abstract][Full Text] [Related]
5. The effect of lateral septum corticotropin-releasing factor receptor 2 activation on anxiety is modulated by stress.
Henry B; Vale W; Markou A
J Neurosci; 2006 Sep; 26(36):9142-52. PubMed ID: 16957071
[TBL] [Abstract][Full Text] [Related]
6. Corticotropin-releasing factor within the central nucleus of the amygdala mediates enhanced ethanol self-administration in withdrawn, ethanol-dependent rats.
Funk CK; O'Dell LE; Crawford EF; Koob GF
J Neurosci; 2006 Nov; 26(44):11324-32. PubMed ID: 17079660
[TBL] [Abstract][Full Text] [Related]
7. Stimulation of lateral septum CRF2 receptors promotes anorexia and stress-like behaviors: functional homology to CRF1 receptors in basolateral amygdala.
Bakshi VP; Newman SM; Smith-Roe S; Jochman KA; Kalin NH
J Neurosci; 2007 Sep; 27(39):10568-77. PubMed ID: 17898228
[TBL] [Abstract][Full Text] [Related]
8. Locomotor suppressive and anxiolytic-like effects of urocortin 3, a highly selective type 2 corticotropin-releasing factor agonist.
Valdez GR; Zorrilla EP; Rivier J; Vale WW; Koob GF
Brain Res; 2003 Aug; 980(2):206-12. PubMed ID: 12867260
[TBL] [Abstract][Full Text] [Related]
9. Selective CRF2 receptor agonists ameliorate the anxiety- and depression-like state developed during chronic nicotine treatment and consequent acute withdrawal in mice.
Bagosi Z; Palotai M; Simon B; Bokor P; Buzás A; Balangó B; Pintér D; Jászberényi M; Csabafi K; Szabó G
Brain Res; 2016 Dec; 1652():21-29. PubMed ID: 27693397
[TBL] [Abstract][Full Text] [Related]
10. A CRF(2) agonist administered into the central nucleus of the amygdala decreases ethanol self-administration in ethanol-dependent rats.
Funk CK; Koob GF
Brain Res; 2007 Jun; 1155():172-8. PubMed ID: 17512918
[TBL] [Abstract][Full Text] [Related]
11. Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal.
Rassnick S; Heinrichs SC; Britton KT; Koob GF
Brain Res; 1993 Mar; 605(1):25-32. PubMed ID: 8467387
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of CRF in the BNST diminishes dysphoria but not anxiety-like behavior in nicotine withdrawing rats.
Qi X; Guzhva L; Yang Z; Febo M; Shan Z; Wang KKW; Bruijnzeel AW
Eur Neuropsychopharmacol; 2016 Sep; 26(9):1378-1389. PubMed ID: 27461514
[TBL] [Abstract][Full Text] [Related]
13. Antagonism of corticotropin-releasing factor attenuates the enhanced responsiveness to stress observed during protracted ethanol abstinence.
Valdez GR; Zorrilla EP; Roberts AJ; Koob GF
Alcohol; 2003 Feb; 29(2):55-60. PubMed ID: 12782246
[TBL] [Abstract][Full Text] [Related]
14. κ opioid regulation of anxiety-like behavior during acute ethanol withdrawal.
Valdez GR; Harshberger E
Pharmacol Biochem Behav; 2012 Jul; 102(1):44-7. PubMed ID: 22487769
[TBL] [Abstract][Full Text] [Related]
15. Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice.
Risbrough VB; Hauger RL; Pelleymounter MA; Geyer MA
Psychopharmacology (Berl); 2003 Nov; 170(2):178-87. PubMed ID: 12845406
[TBL] [Abstract][Full Text] [Related]
16. Human urocortin 2, a corticotropin-releasing factor (CRF)2 agonist, and ovine CRF, a CRF1 agonist, differentially alter feeding and motor activity.
Zorrilla EP; Reinhardt LE; Valdez GR; Inoue K; Rivier JE; Vale WW; Koob GF
J Pharmacol Exp Ther; 2004 Sep; 310(3):1027-34. PubMed ID: 15115804
[TBL] [Abstract][Full Text] [Related]
17. Pre-clinical evidence that corticotropin-releasing factor (CRF) receptor antagonists are promising targets for pharmacological treatment of alcoholism.
Lowery EG; Thiele TE
CNS Neurol Disord Drug Targets; 2010 Mar; 9(1):77-86. PubMed ID: 20201818
[TBL] [Abstract][Full Text] [Related]
18. Differential monoaminergic, neuroendocrine and behavioural responses after central administration of corticotropin-releasing factor receptor type 1 and type 2 agonists.
de Groote L; Peñalva RG; Flachskamm C; Reul JM; Linthorst AC
J Neurochem; 2005 Jul; 94(1):45-56. PubMed ID: 15953348
[TBL] [Abstract][Full Text] [Related]
19. 3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethyl-imidazo[1,2-b]pyridazine: a novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism.
Gehlert DR; Cippitelli A; Thorsell A; Lê AD; Hipskind PA; Hamdouchi C; Lu J; Hembre EJ; Cramer J; Song M; McKinzie D; Morin M; Ciccocioppo R; Heilig M
J Neurosci; 2007 Mar; 27(10):2718-26. PubMed ID: 17344409
[TBL] [Abstract][Full Text] [Related]
20. Spontaneous withdrawal from the triazolobenzodiazepine alprazolam increases cortical corticotropin-releasing factor mRNA expression.
Skelton KH; Nemeroff CB; Owens MJ
J Neurosci; 2004 Oct; 24(42):9303-12. PubMed ID: 15496666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
